{"data":{"id":"us/42-cfr-426.517","jurisdiction":"us","citation":"42 CFR 426.517","heading":"CMS' statement regarding new evidence.","body":"(a) CMS may review any new evidence that is submitted, regardless of whether the Board has stayed the proceedings, including but not limited to new evidence:\n(1) Submitted with the initial complaint;\n(2) Submitted with an amended complaint;\n(3) Produced during discovery;\n(4) Produced when the Board consults with scientific and clinical experts; and\n(5) Presented during any hearing.\n(b) CMS may submit a statement regarding whether the new evidence is significant under § 426.340, by a deadline set by the Board.","path":["Title 42—Public Health","CHAPTER IV—CENTERS FOR MEDICARE \u0026 MEDICAID SERVICES, DEPARTMENT OF HEALTH AND HUMAN SERVICES","SUBCHAPTER B—MEDICARE PROGRAM","PART 426—REVIEW OF NATIONAL COVERAGE DETERMINATIONS AND LOCAL COVERAGE DETERMINATIONS","Subpart E—Review of an NCD"],"source_url":"https://www.ecfr.gov/api/versioner/v1/full/2026-08-25/title-42.xml","current_through":"2026-08-25","vintage":"","retrieved_at":"2026-08-27T02:26:11Z","sha256":"d2d1403925649c45421094473f7fc78004e1407737ad48e4961d9ff5d6908839","source_id":"us-cfr","stale":true,"prev":"us/42-cfr-426.516","next":"us/42-cfr-426.518"},"notice":"GroundRules: Original legal text. Not legal advice."}